Reduction in the cell viability in a dose- and time-dependent manner (at various concentrations: 0.25-4 mg/mL)Reducing the protein expression levels of cyclin D1, CDK4, and CDK6Inducing the apoptosis (at concentrations: 0.5, 1, and 2 mg/mL)Suppressing the invasion of glioblastoma cells (at various concentrations: 0.25 mg/mL, 0.5 mg/mL, 1 mg/mL, and 2 mg/mL)Inhibition of glioma cell proliferation. The gene discussed is CDK4; the disease is central nervous system cancer.